Munich Cancer Registry



- Baseline statistics
- Selection Matrix
- Homepage

Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany

http://www.tumorregister-muenchen.de/en

Cancer statistics: Survival

Year of diagnosis1988-19971998-2011Patients42155Diseases42155Creation date04/01/2013Export date01/03/2013

4.5 m

Population



http://www.tumorregister-muenchen.de/en/facts/surv/surv_C74_E.pdf

C74: Adrenal cancer




Figure 1a. Relative survival of patients with adrenal cancer by period of diagnosis. Included in the evaluation are 125 cases diagnosed between 1988 and 2011.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 1998 to 2009, and are represented by green diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided populationbased statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

	Period of diagnosis							
		1988-	1997	1998+				
		n=	38	n=87				
	Years	obs. %	rel. %	obs. %	rel. %			
	0	100.0	100.0	100.0	100.0			
	1	78.9	79.4	84.6	85.1			
	2	68.4	66.7	78.1	79.4			
	3	55.1	55.9	72.4	72.7			
	4	55.1	53.5	65.0	67.3			
	5	49.6	49.7	62.6	64.3			

Table 1b. Observed (obs.) and relative (rel.) survival of patients with adrenal cancer by period of diagnosis for period 1988-2011 (N=125).




Figure 2a. Observed, expected and relative survival of the total cohort with adrenal cancer. Included in the evaluation are 125 cases diagnosed between 1988 and 2011.

Group						
	Total cohort					
	n=125					
Years	obs. %	rel. %				
0	100.0	100.0				
1	82.8	83.6				
2	75.0	75.5				
3	66.5	67.1				
4	62.0	63.0				
5	58.2	59.8				

Table 2b. Observed (obs.) and relative (rel.) survival of the total cohort with adrenal cancer for period 1988-2011 (N=125).




Figure 3a. Relative survival of patients with adrenal cancer by age category. Included in the evaluation are 125 cases diagnosed between 1988 and 2011.

s
el. %
00.0
73.7
61.7
53.8
47.2
ē

Table 3b. Observed (obs.) and relative (rel.) survival of patients with adrenal cancer by age category for period 1988-2011 (N=125).




Figure 4a. Relative survival of patients with adrenal cancer by TNM staging. For 66 of 125 cases diagnosed between 1988 and 2011 valid data could be obtained for this item. For a total of 62 cases an evaluable classification was established. The accumulated percentage exceeds the 100% value because patients are potientially considered in more than one subgroup. The grey line represents the subgroup of 63 patients with missing values regarding TNM staging (50.4% of 125 patients, the percent values of all other categories are related to n=62). Subgroups with sample size <15 are dropped from the chart.

	TNM staging										
		NO		N+		MO		M1		NA/NOS	
		n=25		n=10		n=21		n=35		n=63	
	Years	obs. %	rel. %								
	0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
	1	96.0	96.1			95.2	95.6	61.3	61.8	88.6	89.0
	2	96.0	93.7			95.2	93.8	51.8	49.1	78.4	79.7
	3	90.9	91.3			95.2	92.1			69.4	69.7
	4	90.9	89.1			89.3	90.2			62.9	65.0
	5	90.9	86.9			89.3	86.1			58.1	60.8

Table 4b. Observed (obs.) and relative (rel.) survival of patients with adrenal cancer by TNM staging for period 1988-2011 (N=91).




Figure 5a. Observed post-progression survival of 75 patients with adrenal cancer diagnosed between 1988 and 2011 (incl. M1). These 75 patients with documented progression events during their course of disease represent 60.0% of the totally 125 evaluated cases. Patients with cancer relapse documented via death certificates only were excluded (n=3, 2.4%). Multiple progression types on different sites are included in the evaluation even when not occuring synchronously. The NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease. Subgroups with sample size <15 are dropped from the chart.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement "not specified" is the only information in registries regarding relapse of the disease. The category "All types" denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100% value because patients are potientially considered in more than one subgroup.

		Type of	f progressior	า	
	All types	Local relapse	Lymph node recurrence	Distant metastasis	NOS
	n=75	n=22	n=4	n=65	n=6
Months	%	%	%	%	%
0	100.0	100.0	100.0	100.0	100.0
12	68.7	72.0		65.4	100.0
24	57.6			52.3	100.0
36	43.9			39.6	
48	43.9			39.6	
60	39.9			35.2	

Table 5b. Observed post-progression survival of patients with adrenal cancer for period 1988-2011 (N=75).

Shortcuts

AS Assembled survival chart (observed, expected, relative) CS Conditional survival DCO Death certificate only. The death certificate provides the only notification to the registry. Munich Cancer Registry, Germany (Tumorregister München) MCR Not available NA NCI National Cancer Institute, USA NOS Not otherwise specified Observed/overall survival (Kaplan-Meier estimate) OS PPS Post-progression survival RS Relative Survival. Ratio of observed and expected survival (derived from the normal population) SEER Surveillance, Epidemiology, and End Results, USA TTP Time to progression Date of entry: Date of diagnosis Event (Progression): First local recurrence, lymph node relapse or distant metastasis, unspecified recurrence First all-cause recurrence is illustrated by survival curves (Kaplan-Meier estimate). First local recurrence, lymph node relapse or distant metastasis are depicted cumulatively, where applicable ("reverse" Kaplan-Meier estimate). UICC Union for International Cancer Control, Geneva

Recommended Citation

Munich Cancer Registry. Survival C74: Adrenal cancer [Internet]. 2013 [updated 2013 Apr 1; cited 2013 May 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/surv/surv_C74_E.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Munich Cancer Registry

Index of figures and tables

Fig./Tb	bl.	Page						
1a	Relative survival by period of diagnosis (chart)							
1b	Survival by period of diagnosis (table)							
2a	Survival of total cohort (chart)	3						
2b	Survival of total cohort (table)	3						
3a	Relative survival by age category (chart)	4						
3b	Survival by age category (table)	4						
4a	Relative survival by TNM staging (chart)	5						
4b	Survival by TNM staging (table)	5						
5a	Observed post-progression survival (chart)	6						
5b	Observed post-progression survival (table)	6						